Международная разработка
ClinicalTrials.gov
Исследования, вмешательства, заболевания, спонсоры, страны и результаты.
Фокус анализа
салметерол
151
записей в выборке
Варианты написания учтены салметерол → salmeterol Подробнее Скрыть
- салметерол → salmeterol проверенная транслитерация · 100% Основание: версионированный словарь · словарь 1.1.0 Поиск: salmeterol, салметерол, сальметерол, салметерола ксинафоат, salmeterol xinafoate, sal meterol
Для поиска доступны 597 478 исследований AACT · ClinicalTrials.gov. Показано совпадений: 78.
Результаты
ClinicalTrials.gov
факт источника
аналитический сигнал
Фильтры реестра По столбцам текущей таблицы Не заданы
| Исследование | Вмешательство / заболевание | Спонсор / страны | Фаза и статус | Сроки / участники | Результаты |
|---|---|---|---|---|---|
| A Multi-Centered Study of the Long-Term Effect of Salmeterol and Albuterol in Cystic Fibrosis ↗ NCT00005110 AACT · ClinicalTrials.gov |
salmeterol
albuterol
Cystic Fibrosis
|
National Center for Research Resources (NCRR) United States | Фаза не указана Приостановлено | — — — — участников | Не найдены Первоисточник ↗ |
| Determine the Safety and Efficacy of (R,R)-Formoterol in the Treatment of Subjects With COPD ↗ NCT00064402 AACT · ClinicalTrials.gov |
salmeterol
arformoterol tartrate inhalation solution
Chronic Obstructive Pulmonary Disease, Chronic Bronchitis, Emphysema
|
Sumitomo Pharma America, Inc. United States | PHASE3 Завершено | 30.04.2002 — 31.03.2004 741 участников | Не найдены Первоисточник ↗ |
| To Evaluate the Long-term Safety of (R,R)-Formoterol in Subjects With COPD ↗ NCT00064415 AACT · ClinicalTrials.gov |
salmeterol
arformoterol
Chronic Obstructive Pulmonary Disease, Chronic Bronchitis, Emphysema
|
Sumitomo Pharma America, Inc. United States | PHASE3 Завершено | 30.06.2002 — 31.12.2004 799 участников | Не найдены Первоисточник ↗ |
| Study Of Asthma And Genetics In Patients To Be Treated With Fluticasone Propionate/Salmeterol Or Salmeterol Xinafoate NCT00102882 AACT · ClinicalTrials.gov |
fluticasone
salmeterol
Asthma
|
GlaxoSmithKline Kenya, Peru, Puerto Rico, United States | PHASE4 Завершено | 31.10.2004 — 31.01.2007 547 участников | Не найдены Первоисточник ↗ |
| Advair® DISKUS® Versus Serevent® DISKUS® For Chronic Obstructive Pulmonary Disease Exacerbations ↗ NCT00115492 AACT · ClinicalTrials.gov |
fluticasone
salmeterol
salmeterol combination product
Pulmonary Disease, Chronic Obstructive
|
GlaxoSmithKline Canada, United States | PHASE4 Завершено | 31.12.2004 — 30.06.2007 797 участников | Не найдены Первоисточник ↗ |
| Two Investigational Drugs in the Prevention of Airway Constriction Brought on by Exercise in Participants With Asthma (0476-911) NCT00127166 AACT · ClinicalTrials.gov |
fluticasone
montelukast sodium
salmeterol
Exercise Induced Asthma
|
Organon and Co Страны не указаны | PHASE3 Завершено | 31.12.2005 — 30.11.2008 154 участников | Опубликованы Первоисточник ↗ |
| ADVAIR® DISKUS® Inhaler (Fluticasone Propionate/Salmeterol) Versus SEREVENT® DISKUS® Inhaler (Salmeterol) For The Treatment Of Chronic Obstructive Pulmonary Disease Exacerbations. ADVAIR® DISKUS® Inhaler and SEREVENT® DISKUS® Inhaler Are Trademarks of the GSK Group of Companies. ↗ NCT00144911 AACT · ClinicalTrials.gov |
salmeterol
Pulmonary Disease, Chronic Obstructive
|
GlaxoSmithKline Canada, United States | PHASE4 Завершено | 31.10.2004 — 31.12.2006 740 участников | Не найдены Первоисточник ↗ |
| Asthma Clinical Research Network (ACRN) Trial - Long-Acting Beta Agonist Response by Genotype (LARGE) NCT00200967 AACT · ClinicalTrials.gov |
salmeterol
beclomethasone hfa
Asthma
|
Milton S. Hershey Medical Center United States | PHASE3 Завершено | 31.12.2004 — 29.02.2008 87 участников | Опубликованы Первоисточник ↗ |
| The Effect of Salmeterol on Eosinophil (EOS) Function NCT00214019 AACT · ClinicalTrials.gov |
fluticasone
salmeterol
Allergic Asthma
|
University of Wisconsin, Madison United States | Фаза не указана Завершено | 30.11.2003 — 31.01.2008 36 участников | Опубликованы Первоисточник ↗ |
| Clinical Evaluation Of GW815SF For Chronic Obstructive Pulmonary Disease (Chronic Bronchitis, Emphysema) ↗ NCT00269126 AACT · ClinicalTrials.gov |
fluticasone
salmeterol
salmeterol combination diskus
Pulmonary Disease, Chronic Obstructive
|
GlaxoSmithKline Japan | PHASE3 Завершено | 28.02.2005 — 31.08.2005 150 участников | Не найдены Первоисточник ↗ |
| A Comparison of the Effects of Tiotropium Inhalation qd and Salmeterol Inhalation Bid on Arterial Blood Gases. ↗ NCT00274534 AACT · ClinicalTrials.gov |
salmeterol
tiotropium
Pulmonary Disease, Chronic Obstructive
|
Boehringer Ingelheim United States | PHASE3 Завершено | 31.12.2000 — 31.07.2003 36 участников | Не найдены Первоисточник ↗ |
| A Multiple Dose Comparison of Tiotropium Inhalation Capsules and Salmeterol Inhalation Aerosol. ↗ NCT00274560 AACT · ClinicalTrials.gov |
salmeterol
tiotropium
Pulmonary Disease, Chronic Obstructive
|
Boehringer Ingelheim Finland, Greece, Italy, Portugal, Sweden, Turkey (Türkiye), United Kingdom, United States | PHASE3 Завершено | 01.05.2002 — — 653 участников | Не найдены Первоисточник ↗ |
| ADVAIR DISKUS® (Fluticasone Propionate/Salmeterol) Inhaler Versus SEREVENT DISKUS® (Salmeterol) Inhlaer On Inflammatory Cells And Markers In Chronic Obstructive Pulmonary Disease. ADVAIR DISKUS® and SEREVENT DISKUS® Inhalers Are Trademarks of the GSK Group of Companies. ↗ NCT00346749 AACT · ClinicalTrials.gov |
salmeterol
Pulmonary Disease, Chronic Obstructive
|
GlaxoSmithKline United States | PHASE4 Прекращено | 31.12.2006 — 31.07.2007 180 участников | Не найдены Первоисточник ↗ |
| Efficacy and Safety of Tiotropium and Salmeterol in Moderate Persistent Asthma Patients Homozygous for B16-Arg/Arg NCT00350207 AACT · ClinicalTrials.gov |
salmeterol
tiotropium bromide
Asthma
|
Boehringer Ingelheim Austria, Belgium, Denmark, Finland, France, Germany, Greece, Italy, Russia, Slovakia, South Africa, Spain, Turkey (Türkiye), United Kingdom | PHASE2 Завершено | 31.07.2006 — — 388 участников | Опубликованы Первоисточник ↗ |
| GSK159802 In Healthy Male Subjects And Asthmatics ↗ NCT00364273 AACT · ClinicalTrials.gov |
salmeterol
gsk159802
Pulmonary Disease, Chronic Obstructive
|
GlaxoSmithKline United Kingdom | PHASE1 Завершено | 24.08.2005 — 06.07.2006 43 участников | Не найдены Первоисточник ↗ |
| Dose Ranging Study for Indacaterol in Japanese Asthma Patients NCT00403754 AACT · ClinicalTrials.gov |
indacaterol
salmeterol
Asthma
|
Novartis Pharmaceuticals Japan | PHASE2 Завершено | 30.11.2006 — 30.11.2007 41 участников | Опубликованы Первоисточник ↗ |
| Safety And Efficacy Of GSK233705 Plus Salmeterol Compared With 2 Active Comparators And Placebo In Subjects With Chronic Obstructive Pulmonary Disease (COPD) ↗ NCT00422604 AACT · ClinicalTrials.gov |
salmeterol
tiotropium
Pulmonary Disease, Chronic Obstructive
|
GlaxoSmithKline Finland, Germany, Netherlands, Russia, United Kingdom | PHASE2 Завершено | 31.10.2006 — 31.05.2007 60 участников | Не найдены Первоисточник ↗ |
| A Blinded Study To Examine The Ability Of PF-610,355 To Open The Airways In Asthmatic Patients. NCT00468975 AACT · ClinicalTrials.gov |
investigational:pf 610
salmeterol
355
Asthma
|
Pfizer Germany, Sweden, United Kingdom | PHASE2 Завершено | 31.05.2007 — — 42 участников | Не найдены Первоисточник ↗ |
| Safety of Exercise and High-dose Salbutamol in Patients With Chronic Obstructive Pulmonary Disease (COPD) Receiving Therapeutic Doses of Indacaterol (QAB 149) and Salmeterol ↗ NCT00531050 AACT · ClinicalTrials.gov |
salmeterol
indacaterol
Chronic Obstructive Pulmonary Disease
|
Novartis Belgium | PHASE2 Завершено | 31.08.2007 — 30.06.2008 27 участников | Опубликованы Первоисточник ↗ |
| Efficacy and Safety Comparison of Steroid or Placebo in Combination With Salmeterol and Tiotropium in COPD ↗ NCT00535366 AACT · ClinicalTrials.gov |
fluticasone
salmeterol
ciclesonide high
ciclesonide low
tiotropium
+2
Pulmonary Disease, Chronic Obstructive
|
Boehringer Ingelheim Belgium, Denmark, Germany, Netherlands | PHASE2 Завершено | 31.10.2007 — — 103 участников | Не найдены Первоисточник ↗ |
| Examining the Link Between Obesity, Inflammation, and Response to Asthma Medications NCT00557180 AACT · ClinicalTrials.gov |
salmeterol
tiotropium bromide
beclomethasone dipropionate hfa
Asthma, Obesity
|
National Jewish Health United States | Фаза не указана Завершено | 31.10.2007 — 28.02.2011 33 участников | Не найдены Первоисточник ↗ |
| Investigation of the 24 Hour Forced Expiratory Flow in 1 Second (FEV1) Profile of a Single Dose of Indacaterol/Mometasone Delivered Via the TWISTHALER® Device in Adult Patients With Persistent Asthma ↗ NCT00557440 AACT · ClinicalTrials.gov |
fluticasone
salmeterol
indacaterol maleate
mometasone
mometasone furoate
+2
Asthma
|
Novartis Belgium, Germany | PHASE2 Завершено | 30.11.2007 — 30.04.2008 37 участников | Опубликованы Первоисточник ↗ |
| Tiotropium Once Daily 18 Mcg Versus Salmeterol Twice Daily 50 Mcg on Time to First Exacerbation in COPD Patients. ↗ NCT00563381 AACT · ClinicalTrials.gov |
salmeterol
tiotropium bromide
Pulmonary Disease, Chronic Obstructive
|
Boehringer Ingelheim Austria, Belgium, Bulgaria, Czechia, Denmark, Finland, France, Germany, Hungary, Israel, Italy, Latvia, Lithuania, Netherlands, Norway, Poland, Portugal, Romania, Russia, Slovakia, Slovenia, Spain, Turkey (Türkiye), Ukraine, United Kingdom | PHASE4 Завершено | 31.01.2008 — — 7 376 участников | Опубликованы Первоисточник ↗ |
| Asthma Clinical Research Network (ACRN) Trial - Tiotropium Bromide as an Alternative to Increased Inhaled Corticosteroid in Patients Inadequately Controlled on a Lower Dose of Inhaled Corticosteroid (TALC) ↗ NCT00565266 AACT · ClinicalTrials.gov |
salmeterol
beclomethasone dipropionate
tiotropium bromide
Asthma
|
Milton S. Hershey Medical Center United States | PHASE3 Завершено | 31.05.2008 — 31.05.2010 210 участников | Опубликованы Первоисточник ↗ |
| Evaluation Inhaled Corticosteroids on Exhaled Nitric Oxide Gas Exchange ↗ NCT00568347 AACT · ClinicalTrials.gov |
fluticasone
salmeterol
fluticasone 100mcg
fluticasone 250
salmeterol 50
salmeterol 50mcg
+3
COPD
|
Arthur F Gelb MD United States | Фаза не указана Завершено | 31.01.2006 — 31.10.2013 39 участников | Не найдены Первоисточник ↗ |
| How Different Beta-2 Receptor Genotypes Affect an Asthmatic's Response to Regular Salmeterol Treatment ↗ NCT00595361 AACT · ClinicalTrials.gov |
salmeterol
Asthma
|
Brigham and Women's Hospital United States | Фаза не указана Завершено | 31.01.2008 — 31.03.2012 30 участников | Опубликованы Первоисточник ↗ |
| Dose Finding Study of CHF 4226 for Treating Patients With COPD ↗ NCT00605891 AACT · ClinicalTrials.gov |
salmeterol
carmoterol chf 4226
Chronic Obstructive Pulmonary Disease
|
Chiesi Farmaceutici S.p.A. Czechia, Germany, Poland, Romania, South Africa, United States | PHASE2 Завершено | 31.10.2006 — 30.06.2007 278 участников | Не найдены Первоисточник ↗ |
| Study of Indacaterol Dosed in the Evening in Patients With Chronic Obstructive Pulmonary Disease (COPD) ↗ NCT00615030 AACT · ClinicalTrials.gov |
salmeterol
indacaterol
Chronic Obstructive Pulmonary Disease (COPD)
|
Novartis France, Germany, Spain | PHASE3 Завершено | 31.01.2008 — 31.08.2008 96 участников | Опубликованы Первоисточник ↗ |
| Confirmatory Dose Finding Study of 2 Dosages of CHF 4226 pMDI (Carmoterol) in Patients With COPD ↗ NCT00640484 AACT · ClinicalTrials.gov |
salmeterol
carmoterol chf 4226
Chronic Obstructive Pulmonary Disease
|
Chiesi Farmaceutici S.p.A. United States | PHASE2 Завершено | 30.04.2008 — 31.10.2008 57 участников | Не найдены Первоисточник ↗ |
| Tiotropium/Salmeterol Inhalation Powder (Spiriva Handihaler and Salmeterol Polyethylene (PE) Capsule) in Chronic Obstructive Pulmonary Disease (COPD) ↗ NCT00662740 AACT · ClinicalTrials.gov |
salmeterol
salmeterol qd
tiotropium
tiotropium spiriva
+1
Pulmonary Disease, Chronic Obstructive
|
Boehringer Ingelheim Austria, Belgium, Canada, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Italy, Latvia, Lithuania, Netherlands, Slovakia, South Korea, Sweden, United States | PHASE3 Прекращено | 15.04.2008 — 21.11.2008 220 участников | Не найдены Первоисточник ↗ |
| Tiotropium/Salmeterol Inhalation Powder in COPD ↗ NCT00668772 AACT · ClinicalTrials.gov |
salmeterol
tiotropium
Pulmonary Disease, Chronic Obstructive
|
Boehringer Ingelheim Austria, Canada, Denmark, Estonia, Finland, France, Germany, Hungary, Italy, Latvia, Lithuania, Netherlands, Slovakia, South Africa, South Korea, Sweden, United States | PHASE3 Прекращено | 15.04.2008 — 21.11.2008 207 участников | Опубликованы Первоисточник ↗ |
| Tiotropium and Salmeterol PK Study in COPD Patients ↗ NCT00673478 AACT · ClinicalTrials.gov |
salmeterol
tiotropium
Pulmonary Disease, Chronic Obstructive
|
Boehringer Ingelheim Belgium, Netherlands | PHASE3 Завершено | 31.05.2008 — — 50 участников | Не найдены Первоисточник ↗ |
| The Effects of Different Long-acting Bronchodilator Medications on Asthma Patients With Different Genetic Variations ↗ NCT00706446 AACT · ClinicalTrials.gov |
fluticasone
salmeterol
budesonide
formoterol
tiotropium bromide
+2
Asthma
|
Brigham and Women's Hospital United States | Фаза не указана Прекращено | 30.06.2008 — 30.09.2011 255 участников | Опубликованы Первоисточник ↗ |
| The Effects of Montelukast on Smokers With Asthma ↗ NCT00712335 AACT · ClinicalTrials.gov |
fluticasone
salmeterol
montelukast
Asthmatic Smokers, Non-asthmatic Smokers
|
Inje University South Korea | PHASE4 Завершено | 28.02.2007 — 31.05.2011 105 участников | Опубликованы Первоисточник ↗ |
| A Study To Investigate The Safety, Toleration And Efficacy of PF00610355 In Chronic Obstructive Pulmonary Disease (COPD) Patients. ↗ NCT00808288 AACT · ClinicalTrials.gov |
salmeterol
pf 00610355
Pulmonary Disease, Chronic Obstructive, Lung Diseases, Lung Diseases, Obstructive
|
Pfizer Argentina, Bulgaria, Croatia, Czechia, Germany, Hungary, Poland, Slovakia, South Africa, Spain, Turkey (Türkiye), United States | PHASE2 Завершено | 31.03.2010 — 31.12.2010 405 участников | Не найдены Первоисточник ↗ |
| Inhaled Corticosteroid Withdrawal in Patients With Chronic Obstructive Pulmonary Disease ↗ NCT00975195 AACT · ClinicalTrials.gov |
fluticasone
salmeterol
tiotropium inhalation
Pulmonary Disease, Chronic Obstructive
|
Boehringer Ingelheim Australia, Belgium, Brazil, Bulgaria, China, Denmark, France, Germany, Greece, Hungary, Italy, Netherlands, New Zealand, Philippines, Poland, Russia, South Africa, Spain, Taiwan, Tunisia, Turkey (Türkiye), Ukraine, United Kingdom | PHASE4 Завершено | 28.02.2009 — 31.07.2013 2 488 участников | Опубликованы Первоисточник ↗ |
| Validation of a New Shortness of Breath With Daily Activities Questionnaire in Patients With Chronic Obstructive Pulmonary Disease ↗ NCT00984659 AACT · ClinicalTrials.gov |
fluticasone
salmeterol
salmeterol combination product
Pulmonary Disease, Chronic Obstructive
|
GlaxoSmithKline United States | PHASE4 Завершено | 29.10.2009 — 01.07.2010 366 участников | Опубликованы Первоисточник ↗ |
| Evaluate Onset of Effect in Patients With Chronic Obstructive Pulmonary Disease (COPD) Treated With Formoterol Turbuhaler® ↗ NCT01048333 AACT · ClinicalTrials.gov |
salmeterol
formoterol
Chronic Obstructive Pulmonary Disease
|
AstraZeneca Italy, Spain, Sweden | PHASE2 Завершено | 31.01.2010 — 31.05.2010 109 участников | Опубликованы Первоисточник ↗ |
| Efficacy and Safety of Different Doses of Indacaterol ↗ NCT01079130 AACT · ClinicalTrials.gov |
salmeterol
indacaterol
Asthma
|
Novartis Pharmaceuticals United States | PHASE3 Завершено | 28.02.2010 — — 511 участников | Опубликованы Первоисточник ↗ |
| Effects of Inhaled Corticosteroids on Sputum Bacterial Load in COPD ↗ NCT01213693 AACT · ClinicalTrials.gov |
salmeterol
fluticasone combination
Chronic Obstructive Pulmonary Disease
|
Università degli Studi di Ferrara Italy | Фаза не указана Завершено | 31.05.2009 — 30.11.2013 60 участников | Не найдены Первоисточник ↗ |
| Interactive Acute Smooth Muscle Effects of Salmeterol and Fluticasone in the Airway ↗ NCT01231230 AACT · ClinicalTrials.gov |
fluticasone
salmeterol
Asthma
|
University of Miami Страны не указаны | Фаза не указана Завершено | 31.05.2007 — 31.08.2010 14 участников | Опубликованы Первоисточник ↗ |
| Effect of Salmeterol on Fluid Clearance From Alveolar-Capillary Membrane in COPD Patients ↗ NCT01271556 AACT · ClinicalTrials.gov |
salmeterol
Salmeterol Effect Against an Acute Alveolar Fluid Clearance Challenge Secondary to Lung Fluid Overload in COPD Patients, Chronic Obstructive Pulmonary Disease, Bronchodilator Agents, Salmeterol
|
University of Milan Italy | Фаза не указана Завершено | 31.12.2008 — 31.07.2009 20 участников | Не найдены Первоисточник ↗ |
| Blacks and Exacerbations on Long Acting Beta Agonists (LABA) vs. Tiotropium (BELT) ↗ NCT01290874 AACT · ClinicalTrials.gov |
salmeterol
formoterol
tiotropium
Asthma
|
Brigham and Women's Hospital United States | PHASE3 Завершено | 30.03.2011 — 31.07.2013 1 070 участников | Опубликованы Первоисточник ↗ |
| QVA149 Versus Fluticasone/Salmeterol in Patients With Chronic Obstructive Pulmonary Disease (COPD) ↗ NCT01315249 AACT · ClinicalTrials.gov |
fluticasone
salmeterol
glycopyrronium qva149
indacaterol
+1
Chronic Obstructive Pulmonary Disease (COPD)
|
Novartis Pharmaceuticals Belgium, Czechia, Estonia, Germany, Hungary, Lithuania, Norway, South Korea, Spain | PHASE3 Завершено | 31.03.2011 — 31.03.2012 523 участников | Опубликованы Первоисточник ↗ |
| A 4-week Dose-Ranging, Dose-Interval, Efficacy, Safety and Tolerability Study of GSK961081 in Subjects With Chronic Obstructive Pulmonary Disease (COPD) ↗ NCT01319019 AACT · ClinicalTrials.gov |
salmeterol
gsk961081
Pulmonary Disease, Chronic Obstructive
|
GlaxoSmithKline Estonia, Germany, Netherlands, Romania, Russia, Slovakia, South Africa, Sweden, Ukraine | PHASE2 Завершено | 31.12.2010 — 30.09.2011 437 участников | Не найдены Первоисточник ↗ |
| Effects of Anticholinergic or Long-Acting Beta 2 Agonist on FeNO and Pulmonary Function in SCI ↗ NCT01355991 AACT · ClinicalTrials.gov |
salmeterol
tiotropium
Spinal Cord Injury
|
James J. Peters Veterans Affairs Medical Center United States | PHASE1 Статус не определён | 31.08.2011 — 31.08.2016 40 участников | Не найдены Первоисточник ↗ |
| Sunovion Brovana Versus Serevent Inspiratory Capacity High Resolution Computed Tomography ↗ NCT01361984 AACT · ClinicalTrials.gov |
salmeterol
nebulized arformoterol
Chronic Obstructive Pulmonary Disease, COPD, Emphysema, Chronic Bronchitis
|
University of California, Los Angeles United States | PHASE4 Статус не определён | 30.06.2011 — 30.06.2013 20 участников | Не найдены Первоисточник ↗ |
| Fluticasone and Salmeterol in Allergic Rhinitis ↗ NCT01388595 AACT · ClinicalTrials.gov |
salmeterol
fluticasone proprionate
Allergic Rhinitis
|
University of Dundee United Kingdom | PHASE4 Завершено | 30.11.2006 — 31.10.2010 23 участников | Не найдены Первоисточник ↗ |
| Efficacy of Inhaling Bronchodilator Medications in Chronic Obstructive Pulmonary Disease ↗ NCT01391559 AACT · ClinicalTrials.gov |
salmeterol
arformoterol
Chronic Obstructive Pulmonary Disease
|
Dartmouth-Hitchcock Medical Center United States | Фаза не указана Завершено | 31.07.2011 — 31.10.2012 20 участников | Опубликованы Первоисточник ↗ |
| Management of Asthma in School-age Children on Therapy ↗ NCT01526161 AACT · ClinicalTrials.gov |
salmeterol
inhaled fluticasone propionate
montelukast
Asthma
|
Professor Warren Lenney Страны не указаны | PHASE4 Завершено | 30.04.2009 — 31.01.2011 229 участников | Не найдены Первоисточник ↗ |
| Effects of Salmeterol on Autonomic Nervous System ↗ NCT01536587 AACT · ClinicalTrials.gov |
salmeterol
Pulmonary Disease, Chronic Obstructive
|
GlaxoSmithKline Germany | PHASE4 Завершено | 31.07.2012 — 30.11.2012 32 участников | Опубликованы Первоисточник ↗ |
| Comparison of Indacaterol 150 mcg Once Daily (o.d.) With Salmeterol/Fluticasone Propionate 50 mcg/500 mcg Twice Daily (b.i.d.) ↗ NCT01555138 AACT · ClinicalTrials.gov |
salmeterol
indacaterol
Chronic Obstructive Pulmonary Disease
|
Novartis Pharmaceuticals Argentina, Colombia, Italy, Malaysia, Mexico, Netherlands, Spain, Switzerland, United Kingdom | PHASE4 Завершено | 29.02.2012 — 28.02.2014 581 участников | Опубликованы Первоисточник ↗ |
| Efficacy and Safety of QMF149 vs. Salmeterol Xinafoate/Fluticasone Propionate in Patients With Chronic Obstructive Pulmonary Disease (COPD) ↗ NCT01636076 AACT · ClinicalTrials.gov |
salmeterol
qmf149
COPD
|
Novartis Pharmaceuticals Australia, Belgium, Bulgaria, Denmark, Finland, Germany, Greece, Hong Kong, Hungary, Israel, Malaysia, Poland, Romania, Singapore, South Africa, Spain, Sweden, Thailand | PHASE2 Завершено | 30.11.2012 — 30.09.2013 629 участников | Опубликованы Первоисточник ↗ |
| A 26-week Treatment Randomized, Double-blind, Double Dummy Study to Assess the Efficacy and Safety of QVA149 ↗ NCT01709903 AACT · ClinicalTrials.gov |
fluticasone
salmeterol
qva149
Chronic Obstructive Pulmonary Disease
|
Novartis Pharmaceuticals Argentina, Chile, China, Taiwan | PHASE3 Завершено | 30.11.2012 — 28.02.2014 744 участников | Опубликованы Первоисточник ↗ |
| Dose-ranging Study ↗ NCT01712451 AACT · ClinicalTrials.gov |
fluticasone
salmeterol
Abdominal Contour Defects
|
Neothetics, Inc United States | PHASE2 Завершено | 31.08.2011 — 31.10.2012 200 участников | Не найдены Первоисточник ↗ |
| Dose Ranging Study ↗ NCT01802723 AACT · ClinicalTrials.gov |
salmeterol
Periumbilical Subcutaneous Adipose Tissue Reduction
|
Neothetics, Inc United States | PHASE2 Завершено | 28.02.2013 — 31.10.2013 472 участников | Не найдены Первоисточник ↗ |
| Nitric Oxyde Concentration in Chronic Obstructive Pulmonary Disease Patients - SANOB Study ↗ NCT01853787 AACT · ClinicalTrials.gov |
salmeterol
formoterol fumarate
Chronic Obstructive Pulmonary Disease (COPD)
|
University of Milan Italy | PHASE4 Завершено | 31.07.2014 — 30.06.2015 49 участников | Не найдены Первоисточник ↗ |
| Effects of Particle Size in Small Airways Dysfunction ↗ NCT01892787 AACT · ClinicalTrials.gov |
salmeterol
formoterol
Asthma
|
University of Dundee United Kingdom | PHASE4 Завершено | 31.07.2013 — 31.12.2014 17 участников | Не найдены Первоисточник ↗ |
| Characterization of Lung Function Profile of Inhaled Tiotropium + Olodaterol Fixed Dose Combination Compared to Fluticasone Propionate + Salmeterol Fixed Dose Combination in COPD Patients ↗ NCT01969721 AACT · ClinicalTrials.gov |
fluticasone
salmeterol
olodaterol
tiotropium
+1
Pulmonary Disease, Chronic Obstructive
|
Boehringer Ingelheim Belgium, Czechia, Denmark, Germany, Hungary, Netherlands, Spain, Sweden | PHASE3 Завершено | 31.10.2013 — 28.02.2015 229 участников | Опубликованы Первоисточник ↗ |
| Study to Evaluate Efficacy/Safety of Combination Budesonide/Indacaterol vs Fluticasone/Salmeterol in Patients With COPD ↗ NCT02055352 AACT · ClinicalTrials.gov |
fluticasone
salmeterol
budesonide
indacaterol
+1
Chronic Obstructive Pulmonary Disease
|
Novartis Pharmaceuticals Argentina, Brazil, Chile, Dominican Republic, Ecuador, Honduras, Mexico, Panama | PHASE4 Завершено | 30.05.2014 — 26.01.2016 222 участников | Опубликованы Первоисточник ↗ |
| Multiple Dose Comparison of Tiotropium Inhalation Capsules, Salmeterol Inhalation Aerosol and Placebo in Patients With Chronic Obstructive Pulmonary Disease (COPD) ↗ NCT02172287 AACT · ClinicalTrials.gov |
salmeterol
tiotropium ba679 br
Pulmonary Disease, Chronic Obstructive
|
Boehringer Ingelheim Страны не указаны | PHASE3 Завершено | 28.02.1999 — — 623 участников | Не найдены Первоисточник ↗ |
| Tiotropium Inhalation Capsules and Salmeterol Inhalation Aerosol on Muscular Efficiency and Resting Energy Expenditure (REE) in Patients With Stable Chronic Obstructive Pulmonary Disease (COPD) ↗ NCT02172794 AACT · ClinicalTrials.gov |
salmeterol
tiotropium
Pulmonary Disease, Chronic Obstructive
|
Boehringer Ingelheim Страны не указаны | PHASE3 Завершено | 31.05.2002 — — 48 участников | Не найдены Первоисточник ↗ |
| Single Blind Cross-over Dose Response Study in Subjects of Two Inhalers of Salmeterol and Fluticasone Propionate ↗ NCT02232087 AACT · ClinicalTrials.gov |
fluticasone
salmeterol
Healthy
|
Kindeva Drug Delivery United Kingdom | PHASE1 Завершено | 31.07.2014 — 31.12.2014 52 участников | Опубликованы Первоисточник ↗ |
| Efficacy, Pharmacokinetics and Safety Comparison of Salmeterol Inhalation Powder Administered Via the HandiHaler® 2 and Serevent® Diskus® in Patients With Chronic Obstructive Pulmonary Disease (COPD) ↗ NCT02242227 AACT · ClinicalTrials.gov |
salmeterol
serevent diskus
Pulmonary Disease, Chronic Obstructive
|
Boehringer Ingelheim Страны не указаны | PHASE2 Завершено | 30.09.2005 — — 111 участников | Не найдены Первоисточник ↗ |
| Free Combinations of Tiotropium Inhalation Powder Capsule + Salmeterol Metered Dose Inhaler, Tiotropium Inhalation Powder Capsule and Salmeterol Metered Dose Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD) ↗ NCT02242253 AACT · ClinicalTrials.gov |
salmeterol
tiotropium
Pulmonary Disease, Chronic Obstructive
|
Boehringer Ingelheim Страны не указаны | PHASE2 Завершено | 30.09.2003 — — 97 участников | Не найдены Первоисточник ↗ |
| In Vivo Specificity of KUC 7483 CL Co-administered With Bisoprolol, Propranolol, and Acipimox in Healthy Male Subjects ↗ NCT02256722 AACT · ClinicalTrials.gov |
salmeterol
acipimox
bisoprolol
kuc 7483 cl
propranolol
+2
Healthy
|
Boehringer Ingelheim Страны не указаны | PHASE1 Завершено | 31.10.2005 — — 12 участников | Не найдены Первоисточник ↗ |
| Evaluating the Safety and Efficacy of LIPO-202 for the Reduction of Central Abdominal Bulging Due to Subcutaneous Fat ↗ NCT02397499 AACT · ClinicalTrials.gov |
salmeterol
Central Abdominal Bulging
|
Neothetics, Inc United States | PHASE3 Завершено | 30.04.2015 — — 800 участников | Не найдены Первоисточник ↗ |
| Evaluating the Safety and Efficacy of LIPO-202 for the Reduction of Central Abdominal Bulging Due to Subcutaneous Fat (AbCONTOUR2) ↗ NCT02398188 AACT · ClinicalTrials.gov |
salmeterol
Central Abdominal Bulging
|
Evofem Inc. United States | PHASE3 Завершено | 09.04.2015 — 29.10.2015 793 участников | Опубликованы Первоисточник ↗ |
| A Study to Compare the Efficacy of Fluticasone Furoate/Vilanterol Inhalation Powder With Usual Inhaled Corticosteroids (ICS)/Long Acting Beta Agonists (LABA) in Persistent Asthma ↗ NCT02446418 AACT · ClinicalTrials.gov |
fluticasone
salmeterol
budesonide
fluticasone furoate
formoterol fumarate
vilanterol
+3
Asthma
|
GlaxoSmithKline France, Germany | PHASE3 Завершено | 09.07.2015 — 20.07.2017 423 участников | Опубликованы Первоисточник ↗ |
| Pharmacological Properties of Salmeterol ↗ NCT02558088 AACT · ClinicalTrials.gov |
salmeterol
Pharmacokinetics in Healthy Young Men
|
University of Copenhagen Denmark | PHASE4 Завершено | 30.09.2014 — 31.07.2016 11 участников | Не найдены Первоисточник ↗ |
| Safety and Efficacy Study of LIPO-202 for the Reduction of Central Abdominal Bulging in Obese Subjects ↗ NCT02568319 AACT · ClinicalTrials.gov |
salmeterol
Central Abdominal Bulging
|
Neothetics, Inc United States | PHASE2 Завершено | 30.09.2015 — — 120 участников | Не найдены Первоисточник ↗ |
| Cardiovascular Function in COPD Patients ↗ NCT03055988 AACT · ClinicalTrials.gov |
fluticasone
salmeterol
olodaterol
tiotropium
+1
Pulmonary Disease, Chronic Obstructive
|
Boehringer Ingelheim Germany | PHASE4 Завершено | 29.03.2017 — 26.03.2018 76 участников | Опубликованы Первоисточник ↗ |
| The ENERGITO® 2 Study Compares 2 Inhaled Medicines for Chronic Obstructive Pulmonary Disease (COPD). One Medicine is a Combination of Tiotropium and Olodaterol (Stiolto®) Taken Using the Respimat® Inhaler and the Other Medicine is a Combination of Fluticasone and Salmeterol Taken Using the Diskus ↗ NCT03240575 AACT · ClinicalTrials.gov |
fluticasone
salmeterol
olodaterol
tiotropium
+1
Pulmonary Disease, Chronic Obstructive
|
Boehringer Ingelheim United States | PHASE4 Завершено | 14.08.2017 — 06.05.2019 302 участников | Опубликованы Первоисточник ↗ |
| Generation of Biological Samples Positive to Salmeterol for Anti-Doping Control ↗ NCT04195867 AACT · ClinicalTrials.gov |
salmeterol
Healthy Volunteers
|
Parc de Salut Mar Spain | PHASE1 Завершено | 20.11.2018 — 08.01.2019 4 участников | Не найдены Первоисточник ↗ |
| Mechanisms of Adverse Effects of Long-Acting Beta-Agonists in Asthma ↗ NCT04503460 AACT · ClinicalTrials.gov |
salmeterol
salmeterol fluticasone
Asthma
|
Imperial College London United Kingdom | PHASE4 Статус не определён | 23.07.2021 — 30.09.2024 24 участников | Не найдены Первоисточник ↗ |
| Replication of the POET-COPD Trial in Healthcare Claims Data ↗ NCT05083429 AACT · ClinicalTrials.gov |
salmeterol
tiotropium
Chronic Obstructive Pulmonary Disease
|
Brigham and Women's Hospital United States | Фаза не указана Завершено | 22.09.2020 — 09.08.2021 8 716 участников | Не найдены Первоисточник ↗ |
| Muscle Anabolic Response to β2-adrenergic Stimulation With Increased Amino Acid Availability. ↗ NCT06654986 AACT · ClinicalTrials.gov |
salmeterol
amino acid availability
Healthy
|
University of Copenhagen Denmark | Фаза не указана Набор участников | 31.10.2024 — 18.12.2026 36 участников | Не найдены Первоисточник ↗ |
| Salmeterol Effect on Exercise Performance ↗ NCT06655012 AACT · ClinicalTrials.gov |
salmeterol
Healthy
|
University of Copenhagen Denmark | Фаза не указана Набор участников | 31.10.2024 — 31.12.2026 36 участников | Не найдены Первоисточник ↗ |